Studies on Aldosterone and Vascular Function
This study has been completed.
Sponsor:
Yale University
Collaborator:
Pfizer
Information provided by:
Yale University
ClinicalTrials.gov Identifier:
NCT00700479
First received: December 25, 2007
Last updated: June 17, 2008
Last verified: June 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
A randomized crossover trial to determine the effects of sodium loading and aldosterone infusion on endothelial function in normal subjects.
| Condition | Intervention | Phase |
|---|---|---|
|
Inflammation |
Drug: aldosterone Dietary Supplement: low or high sodium diet Drug: placebo |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Pharmacodynamics Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Diagnostic |
| Official Title: | Studies on Aldosterone and Vascular Function |
Further study details as provided by Yale University:
Primary Outcome Measures:
- Flow mediated dilation brachial artery [ Time Frame: 0 and 4 hours ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 20 |
| Study Start Date: | January 2006 |
| Study Completion Date: | June 2008 |
| Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: A
Aldosterone plus low salt diet
|
Drug: aldosterone
4 hour infusion
Dietary Supplement: low or high sodium diet
|
|
Experimental: B
Aldosterone plus high sodium diet
|
Drug: aldosterone
4 hour infusion
Dietary Supplement: low or high sodium diet
|
|
Placebo Comparator: C
Placebo plus low sodium diet
|
Dietary Supplement: low or high sodium diet
Drug: placebo
placebo
|
|
Placebo Comparator: D
placebo plus high sodium diet
|
Dietary Supplement: low or high sodium diet
Drug: placebo
placebo
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Healthy subjects age >18 years
Exclusion Criteria:
- Any chronic medical disease or chronic use of medications
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00700479
Locations
| United States, Connecticut | |
| Yale University School of Medicine | |
| New Haven, Connecticut, United States, 06510 | |
Sponsors and Collaborators
Yale University
Pfizer
Investigators
| Principal Investigator: | Stuart Katz, MD | Yale School of Medicine |
More Information
No publications provided
| Responsible Party: | Stuart Katz, Yale School of Medicine |
| ClinicalTrials.gov Identifier: | NCT00700479 History of Changes |
| Other Study ID Numbers: | 602001143 |
| Study First Received: | December 25, 2007 |
| Last Updated: | June 17, 2008 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Yale University:
|
vascular endothelium nitric oxide aldosterone vascular biology |
Additional relevant MeSH terms:
|
Inflammation Pathologic Processes |
ClinicalTrials.gov processed this record on May 22, 2013